A first-in-human, single-centre, placebo-controlled, randomized, double-blind study in healthy subjects to evaluate safety, tolerability, pharmacokinetics and food effect after oral single and multiple ascending dosing of KAND567

Completed

• Conditions: MS; Multiple sclerosis; 10012303

• Registration Number: NL-OMON44294
• Lead Sponsor: Kancera AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 98

Inclusion Criteria

Healthy male and female

Exclusion Criteria

Clinical significant abnormalities at medical research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The safety endpoint parameters are frequency and severity of adverse events,<br /><br>vital signs, electrocardiography (ECG), safety laboratory tests and urinalysis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The pharmacokinetic parameters. </p><br>